CDA | Evidence Driven
CDA | Evidence Driven

Adcetris for Hodgkin Lymphoma Resubmission – Details

Details

Files
Generic Name:
Brentuximab Vedotin
Project Status:
Complete
Therapeutic Area:
Hodgkin lymphoma (HL)
Manufacturer:
Seattle Genetics, Inc.
Brand Name:
Adcetris (Resubmission)
Project Line:
Reimbursement Review
Project Number:
PC0145-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
50 mg
Tumour Type:
Lymphoma
Indications:
Hodgkin Lymphoma
Funding Request:
For the treatment of patients with HL after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates
Sponsor:
Seattle Genetics, Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Brentuximab (Adcetris) HL Resubmission – pERC Final Recommendation Final Recommendation March 7, 2019 View PDF
Brentuximab (Adcetris) HL Resubmission – Final Clinical Guidance Report Guidance Reports March 7, 2019 View PDF
Brentuximab (Adcetris) HL Resubmission – Final Economic Guidance Report Guidance Reports March 7, 2019 View PDF
Brentuximab (Adcetris) HL Resubmission – pERC Initial Recommendation Initial Recommendation January 4, 2019 View PDF
Brentuximab (Adcetris) HL Resubmission – PAG Feedback on Initial Recommendation Feedback March 7, 2019 View PDF
Brentuximab (Adcetris) HL Resubmission – Submitter Feedback on Initial Recommendation Feedback March 7, 2019 View PDF
Brentuximab (Adcetris) HL Resubmission – Patient Feedback on Initial Recommendation Feedback March 7, 2019 View PDF
Brentuximab (Adcetris) HL Resubmission – Clinician Feedback on Initial Recommendation Feedback March 7, 2019 View PDF
Brentuximab (Adcetris) HL Resubmission – Patient COI Declarations COI Declarations March 7, 2019 View PDF
Brentuximab (Adcetris) HL Resubmission – Clinician COI Declarations COI Declarations March 7, 2019 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : March 22, 2019